

To explore the metabolic pattern of uninvolved skin, psoriatic skin and corticosteroid treated psoriatic skin

¹Dr. Perumalla Nataraj, ²Dr. Haritha Komaravelli

¹ Associate Professor, RVM Institute of Medical Sciences & Research Centre, Laxmakkapally, Telangana, India

² Assistant Professor, RVM Institute of Medical Sciences & Research Centre, Laxmakkapally, Telangana, India

Corresponding Author:

Dr. Haritha Komaravelli (nrajperumalla@gmail.com)

Date of acceptance: 11-01-2023

Abstract

Aim: The aim of the present study was to explore the metabolic pattern of uninvolved skin, psoriatic skin and corticosteroid treated psoriatic skin.

Methods: Twelve patients with stable light to moderate plaque psoriasis volunteered to participate in the study. Eight of the patients were men and four were women (not pregnant or nursing) with a median age of 52 (range 28-75) years.

Results: We observed no differences in the tissue levels of creatine, glycine, lactate or phosphocholine between the three types of samples. Seven of the patients showed a good clinical effect of topical corticosteroid treatment (at least 40% reduction of clinical score), whereas three patients had poor effect (less than 40% reduction of clinical score). We found metabolic changes that were different in these two patient groups for five of the metabolites ($p < 0.05$, Mann-Whitney). In skin samples from patients with good treatment results, glucose, myo-inositol, GPC and glycine increased with treatment, whereas choline decreased.

Conclusion: This MR method demonstrates that metabolism in psoriatic skin becomes similar to that of uninvolved skin after effective corticosteroid treatment. MR profiling of skin lesions reflect metabolic alterations related to pathogenesis and treatment effects

Keywords: Tissue, metabolites, corticosteroids, psoriasis treatment, MR spectroscopy

Introduction

Psoriasis is a common immune-mediated disease that affects the skin and joints. The cause of the disease remains unknown. Many patients have a genetic predisposition. The disease affects around 2-3% of the population worldwide. Clinically, psoriatic plaques are characterized by sharply demarcated erythematous lesions with thick silvery scales, often distributed in a symmetrical pattern. Histopathologically there is hyper proliferation of epidermal cells and an inflammatory cell infiltrate^[1]. There is increasing awareness that psoriasis is a multisystem affection with substantial comorbidity, particularly of cardiovascular diseases and metabolic syndrome^[2]. The course is that of a chronic, relapsing disease which requires long term treatment. Various topical and systemic treatment options exist for psoriatic lesions. Topical corticosteroids remain the cornerstone, either used as monotherapy or in combination with other treatment modalities. These agents exert anti-inflammatory and immunosuppressive effects by stimulation or inhibition of the genes

involved in inflammatory pathways, including inhibition of cytokine production and reduction of such mediators of inflammation as prostaglandins and leukotrienes, inhibition of T-cell proliferation and T-cell dependent immunity, and suppression of fibroblast and endothelial cell functions^[3,4]. Corticosteroids also have anti-proliferative effects, by delaying the onset of DNA synthesis and decreasing the mitotic rate^[5].

Metabolomics is an emerging field in the omics family that concerns with the identification and quantitation of small molecules including amino acids, carbohydrates and their derivatives, biogenic amines, lipids, and more. Current work on the metabolomics of psoriasis is very limited with only a number of published papers. Kamleh and his colleagues have discovered changes in free-circulating amino acids, namely, arginine, proline, alanine, glutamate, aspartate, glycine, serine and threonine, which levels are elevated in the plasma of patient psoriasis. The levels of amino acids revert to normal after the biological treatment with TNF α receptor blocker Etanercept^[6]. In another study by Armstrong *et al.*, higher concentrations of alpha ketoglutaric acid and glucuronic acid and lower levels of asparagine and glutamine were determined in psoriasis patients' serum. In addition, patients with both psoriasis and psoriatic arthritis showed higher levels of lignoceric acid and a lower level of alpha ketoglutaric acid in the serum when compared to patients with psoriasis alone^[7].

The aim of the present study was to explore the metabolic pattern of uninvolved skin, psoriatic skin and corticosteroid treated psoriatic skin.

Methods

Twelve patients with stable light to moderate plaque psoriasis volunteered to participate in the study. Eight of the patients were men and four were women (not pregnant or nursing) with a median age of 52 (range 28-75) years. None of the patients used systemic treatment for psoriasis. Three patients were on systemic medication for non-dermatological reasons: irbesartan (hypertension) and terbinafine (tinea unguium), aspirin and pravastatin (hypercholesterolemia) and amlodipine (hypertension). The Regional Committee for Medical and Health Research Ethics, Central Norway approved the study protocol, and all patients signed a written informed consent form.

Study design

Two symmetrical psoriatic lesions were chosen for each patient. The psoriatic lesions were localized at elbows (n = 4), knees (n = 4), upper back (n = 1), hips (n = 1), flanks (n = 1) and buttocks (n = 1). After at least two weeks of treatment with only emollient (Locobase®, Yamanouchi), one plaque was assigned for continued treatment with emollient. The other chosen psoriatic lesion was treated once daily (evening time) with the very potent corticosteroid clobetasol propionate ointment 0.05% (Dermovate®, GlaxoSmithKline). In addition, the emollient was used both on the lesion treated with corticosteroid and the control lesion according to needs. Both psoriatic lesions were evaluated clinically before the start of the treatment and after four weeks of treatment. The severity of scaling, erythema and infiltration of the lesions was scored on a scale from 0-4 for each parameter (0 absent and 4 severe). After four weeks, three punch biopsies (4 mm) were taken after local anaesthesia with lidocaine with epinephrine: from uninvolved skin, from psoriatic skin and from corticosteroid treated psoriatic skin in the same body area.

Sample treatment

The punch biopsy samples were put in a cryo-tube and frozen in liquid nitrogen (-195.8 °C) within one minute after tissue resection, and further stored in liquid nitrogen until MR analysis. Samples weighed 21.9 mg on average (range from 11.6 to 35.7 mg). MR

spectroscopy The MR experiments were performed as previously described [8]. Briefly, samples were thawed on an iceblock to provide a cold environment and transferred to a 4 mm MAS rotor (total sample volume 50 μ L) containing 40 μ L phosphate buffered saline with TSP (1 mM). The rotor was thereafter placed in a Bruker AVANCE DRX600 spectrometer equipped with a $^1\text{H}/^{13}\text{C}$ MAS probe with gradients (Bruker BioSpin GmbH, Germany). During signal acquisition, which started within 42 minutes in average after sample thawing (maximum 1 hour and 35 minutes), the samples were spun at 5 kHz and kept at 4 °C. One-dimensional ^1H spectra were recorded, using a spin-echo sequence which suppresses broad peaks and the water signal. The resulting spectra are highly resolved, with relatively enhanced signals from small metabolites. Spectral assignments were performed based on metabolite appearances in previously recorded MR spectra of intact human tissue [9, 10] and in MR spectra of extracts from skin tissue [11]. Totally 17 metabolites were assigned.

Analysis of MR spectra

The spectral region 4.7 to 3.0 ppm was used for peak area calculations, which was performed using the curve fitting program PeakFit version 4 (SeaSolve Inc, USA (MA)), by combined Lorentzian and Gaussian functions (Voigt area) for curve area estimation. Areas were calculated for the nine peaks arising from glucose, lactate, myo-inositol, glycine, taurine, glycerophosphocholine (GPC), phosphocholine (PCho), choline and creatine. The program uses a least squares function to optimize the fit to the real spectrum, and the correlation factor which describes the goodness of fit was better than 0.95 for all area calculations. To obtain a semi-quantitative measure for each metabolite, its peak area was normalized to the total peak area of all nine metabolites for every spectrum. Kruskal-Wallis multiple sample analysis was applied for paired comparisons of metabolite content in the three types of skin samples. Differences in tissue metabolites between corticosteroid treated and untreated psoriatic skin were calculated for all patients. Metabolic changes ascribed to corticosteroid treatment were compared between the group with poor (N = 4) and good (N = 8) clinical effect using Mann-Whitney significance test. Statistical analyses were performed using SPSS (SPSS 16, SPSS Inc.).

Histopathology

Tissue samples were stored in liquid nitrogen for 20 months after MAS MRS analysis. For histological evaluation, samples were thawed and immersed in 4% buffered formaldehyde fixative solution for 24 hours, followed by embedment in paraffin. From each block, one 5 μ m tissue section was cut and stained with hematoxylin, erythrosine and saffron (HES). The microscopic sections were photographed with a digital camera, and the relative amounts of epidermis, dermis and subcutaneous tissue were determined by point counting [12]. Briefly, the micrographs were overlaid with a randomly positioned point grid, and the number of points falling on each of the three tissue components was counted, considering the stratum corneum as part of the epidermis. The relative number of points falling on one particular component was taken as an estimate of the section area occupied by the respective tissue element. The area fraction thus obtained is an unbiased estimate of the corresponding volume fraction in the tissue sample, provided the section is chosen randomly.

Results

Table 1: Statistically significantly different metabolites and their ratios from targeted analysis

Metabolite	p-value	Psoriasis mean μM \pm SD
Methionine Sulfoxide	6.06E-06	0.88 \pm 0.37
Non-acylcarnitine	0.002	0.04 \pm 0.01
Glutamate	0.002	92.85 \pm 66.43

Ratio of citrulline to ornithine	0.002	0.37 ± 0.13
Ratio of acetylcarnitine to free carnitine	0.004	0.17 ± 0.08
Ratio of short-chain acylcarnitines to free carnitine	0.005	0.18 ± 0.08
Phosphatidylcholine diacetyl C36:6	0.006	0.68 ± 0.27
Ratio of esterified to free carnitine	0.006	0.25 ± 0.1
Pamela L'Carnitine	0.011	0.019 ± 0.006
Ornithine	0.011	99.79 ± 29.44
Phenylalanine	0.026	82.91 ± 18.96
Dodecanoylcarnitine	0.036	0.1 ± 0.036
Decadienylcarnitine	0.044	0.069 ± 0.021
Ratio of putrescine to ornithine	0.013	0.001 ± 0.001
Ratio of long-chain acylcarnitines to free carnitine	0.027	0.004 ± 0.001

Metabolites from the targeted approach that differ statistically significantly in the serum of subjects with plaque psoriasis from controls are shown in Table 1. We found the differences in acylcarnitine levels, mainly in the concentrations of non-acylcarnitine (C9), dodecanoylcarnitine (C12), decadienylcarnitine (C10.2) which are all lower in concentrations in psoriasis subjects' serum. Phosphatidylcholine diacyls (PC aa) C36:5/C36:6 and phosphatidylcholine acyl-alkyls (PC ae) C38:0/C40:6 all showed higher levels in controls' serum. Statistically significantly differing levels of amino acids were found to be for glutamate (Glu), ornithine (Orn), phenylalanine (Phe), and methioninesulfoxide (Met.SO). Amino acid concentrations in samples were statistically significantly higher in psoriasis subjects compared to controls. Ratios of acylcarnitine to free carnitine (C2...C0), short-chain acylcarnitines to free carnitine (X.C2.C3...C0), citrulline to ornithine (Cit... Orn), esterified to free carnitine (Total.AC...C0), putrescine to ornithine (Putrescine...Orn), and long-chain acylcarnitines to free carnitine ([C16 + C18]/C0) were all statistically significantly higher in controls, whereas the levels of the fraction of sulfoxidized methionine of the unmodified methionine pool (Met.SO...Met) were higher in psoriasis patients.

Patients

All patients experienced a reduced degree of psoriatic affection after four weeks of treatment with corticosteroid ointment. Eight of the patients experienced at least 40% reduction of the clinical score of the skin, of which four patients had almost complete normalization of the skin (score grade 1 for erythema and infiltration, no scaling). Four patients had 40% or less reduction of clinical skin scoring, and were considered to have poor effect of the corticosteroid treatment. Concerning the untreated psoriatic lesions, five of the patients showed no change over four weeks, three experienced less scaling after application of emollient whereas in two patients a worsening was noted.

Histology

All samples could be evaluated with respect to tissue composition after MR analysis and long-term storage in liquid nitrogen. Epidermis was thicker in psoriasis lesions, and comprised a significantly larger fraction of the biopsies both in untreated (12%) and corticosteroid treated (9%) skin than in the uninvolved skin (3%) ($p < 0.05$, ANOVA). All patients but one had lower epidermal fraction in corticosteroid treated than in untreated psoriatic skin, with about 40% reduction in epithelial thickness. The one patient with an increased thickness of epidermis after corticosteroid treatment was also clinically scored as showing poor response to treatment.

Metabolites

The MR spectra of the skin samples showed signals from numerous small molecular weight

metabolites and lipids. The nine metabolites were detectable in all spectra, and were identified as cell building blocks (amino acids and choline compounds), osmolytes (taurine) and metabolites involved in energy consumption (glucose and lactate). Peak areas of the nine selected metabolites could be calculated for all samples. In addition, the anesthetic lidocaine contributed significantly to most spectra, giving rise to a total of seven peaks. Statistical analysis showed that the tissue content of glucose, myoinositol, taurine, GPC and choline were different in the three types of sample ($p < 0.05$, Kruskal-Wallis). The levels of myoinositol and glucose were highest in uninvolved skin and lowest in psoriatic skin, whereas those of taurine and choline were highest in psoriatic skin and lowest in uninvolved skin. The levels of GPC were highest in corticosteroid treated skin and lowest in psoriatic skin. We observed no differences in the tissue levels of creatine, glycine, lactate or phosphocholine between the three types of sample. Seven of the patients showed a good clinical effect of topical corticosteroid treatment (at least 40% reduction of clinical score), whereas three patients had poor effect (less than 40% reduction of clinical score). We found metabolic changes that were different in these two patient groups for five of the metabolites ($p < 0.05$, Mann-Whitney). In skin samples from patients with good treatment results, glucose, myoinositol, GPC and glycine increased with treatment, whereas choline decreased.

Discussion

The elevated levels of amino acids in the serum of psoriasis patients established in this present study can be linked to the higher demand for amino acids in the hyper proliferative epidermis, where de novo synthesis of proteins is upregulated and the rate of mitosis in basal keratinocytes is increased compared to non-lesional skin^[1].

We found that psoriatic skin had significantly lower levels of myoinositol and glucose, and higher levels of choline than uninvolved skin. These differences between affected and healthy tissue of psoriatic patients are analogous to the differences found between affected and healthy tissue in cancer patients. Both psoriasis and cancer are characterized by high cellular proliferation rates. Similarities in metabolic profiles are thus expected, in particular higher availability of nutrients for the synthesis of new biomass. Lower levels of glucose are presumably due to high glucose turnover in rapidly proliferating cells, whereas increased choline levels are associated with the need of cellular building blocks^[13]. In a previous study by Kim *et al.*^[10], perchloric acid extracts of skin biopsy samples from psoriasis plaques, malignant melanomas and control skin were analyzed with MR spectroscopy and GC/MS. Several metabolic ratios and concentrations were altered in psoriasis plaques compared to uninvolved psoriatic skin. The majority of metabolite concentrations were higher in psoriasis plaque. For metabolites analyzed in our study, Kim *et al.*^[10] reported higher creatine-to-glycine ratio, higher lactate and lower glycine in psoriatic plaque than in noninvolved psoriatic skin.

We observed increased levels of glucose and myoinositol, and decreased levels of choline in steroid treated skin from responders, which indicate that the metabolic profile approaches that of uninvolved skin when treatment is effective. This metabolic change probably reflects the anti-proliferative effect of steroids, which leads to a decreased demand of nutrients for biomass synthesis. The decreased choline levels can also reflect the anti-inflammatory effect of corticosteroid treatment, as choline is known to accumulate in inflammatory processes^[14]. Thus, the metabolic profile of tissue can be a molecular indicator of treatment effects and provide insight into specific pathways of drug action. There is an increased understanding of changes in molecular and cellular processes in psoriasis, and the roles and functions of several macromolecules are established. The method applied in this study can portray the small organic molecules that are substrates, intermediates and end products in cellular processes. Their function and role in psoriasis is not established. In order to understand how drugs affect metabolic pathways, tissue metabolic analysis should be combined with molecular profiling^[15].

This study was performed on a small number of patients (N = 12), where three of the patients

were receiving systematic treatment for other conditions. These ongoing, systematic treatments are unlikely to influence the observed metabolic patterns and alterations in the skin. However, a larger population without patients receiving systematic treatments will rule out possible biasing and provide more robust data. This study demonstrates the potential value of metabolic profiling as a provider of information complementary to clinical and molecular evaluation, including information which may shed new light on the changes occurring with treatment. By modifying the experimental procedures we may obtain absolute quantitative measures of tissue metabolites ^[16]. Furthermore, metabolic profiling can be combined with subsequent analysis of gene expression profiles ^[15, 17], thus enabling detailed and complex information on several molecular levels. Although demonstrated for topical corticosteroid treatment, metabolic profiling of psoriatic lesions can also be applied in a diverse range of psoriasis treatment regimens, providing increased understanding of the processes of pathogenesis and their reversal due to treatment. MR spectroscopy of skin biopsies may also be utilized to obtain metabolic status of other skin conditions.

Conclusion

This study demonstrated detectable differences in tissue metabolites between uninvolved skin, psoriatic skin and corticosteroid treated psoriatic skin. We also found that metabolic differences induced by corticosteroid treatment were related to the actual therapeutic effect. The application of MR spectroscopy in dermatological research provides information about tissue metabolites, thus presenting a novel approach for studies of pathogenesis and treatment effects in the skin.

References

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. *N Engl. J Med.* 2009;361:496-509.
2. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. *The American journal of medicine.* 2009 Dec;122(12):1150-e1.
3. Hughes J, Rustin M. Corticosteroids. *Clinics in dermatology.* 1997 Sep;15(5):715-21.
4. Reich K, Bewley A. What is new in topical therapy for psoriasis? *Journal of the European Academy of Dermatology and Venereology.* 2011 Jun;25:15-20.
5. Millikan LE. *Drug therapy in dermatology.* CRC Press; c2000 Jul.
6. Kamleh MA, Snowden SG, Grapov D, Blackburn GJ, Watson DG, Xu N, *et al.* LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNF α treatment. *Journal of proteome research.* 2015 Jan;14(1):557-66.
7. Armstrong AW, Wu J, Johnson MA, Grapov D, Azizi B, Dhillon J, *et al.* Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. *F1000 Research;* c2014. p. 3.
8. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. *NMR in Biomedicine: An International Journal Devoted to the Development and Application of Magnetic Resonance *In vivo*.* 2006 Feb;19(1):30-40.
9. Sitter B, Sonnewald U, Spraul M, Fjösne HE, Gribbestad IS. High- resolution magic angle spinning MRS of breast cancer tissue. *NMR in Biomedicine: An International Journal Devoted to the Development and Application of Magnetic Resonance *in vivo*.* 2002 Aug;15(5):327-37.
10. Martínez- Bisbal MC, Martí- Bonmatí L, Piquer J, Revert A, Ferrer P, Llacer JL, *et al.* ¹H and ¹³C HR- MAS spectroscopy of intact biopsy samples *ex vivo* and *in vivo* ¹H MRS study of human high grade gliomas. *NMR in Biomedicine: An International Journal Devoted to the Development and Application of Magnetic Resonance *in vivo*.* 2004 Jun;17(4):191-205.

11. Kim YH, Orenberg EK, Faull KF, Wade-Jardetzky NG, Jardetzky O. ¹H NMR spectroscopy: an approach to evaluation of diseased skin *in vivo*. *Journal of investigative dermatology*. 1989 Feb;92(2):210-6.
12. Weibel ER, Kistler GS, Scherle WF. Practical stereological methods for morphometric cytology. *The Journal of cell biology*. 1966 Jul;30(1):23-38.
13. Bathen TF, Sitter B, Sjøbakk TE, Tessem MB, Gribbestad IS. Magnetic Resonance Metabolomics of Intact Tissue: A Biotechnological Tool in Cancer Diagnostics and Treatment Evaluation MR Metabolomics of Cancer Tissue. *Cancer research*. 2010 Sep;70(17):6692-6.
14. Waarde AV, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. *Current pharmaceutical design*. 2008 Nov;14(31):3326-39.
15. Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, *et al.* Merging transcriptomics and metabolomics-advances in breast cancer profiling. *BMC cancer*. 2010 Dec;10(1):1-4.
16. Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, *et al.* Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. *NMR in Biomedicine: An International Journal Devoted to the Development and Application of Magnetic Resonance in vivo*. 2010 May;23(4):424-31.
17. Cuperlovic-Culf M, Chute IC, Culf AS, Touaibia M, Ghosh A, Griffiths S, *et al.* ¹H NMR metabolomics combined with gene expression analysis for the determination of major metabolic differences between subtypes of breast cell lines. *Chemical Science*. 2011;2(11):2263-70.